Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial

IMPORTANCE: The GeparSixto trial provided evidence that the addition of neoadjuvant carboplatin to a regimen consisting of anthracycline, taxane, and bevacizumab increases pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Whether BRCA1 and BRCA2 germli...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JAMA Oncol
Asıl Yazarlar: Hahnen, Eric, Lederer, Bianca, Hauke, Jan, Loibl, Sibylle, Kröber, Sandra, Schneeweiss, Andreas, Denkert, Carsten, Fasching, Peter A., Blohmer, Jens U., Jackisch, Christian, Paepke, Stefan, Gerber, Bernd, Kümmel, Sherko, Schem, Christian, Neidhardt, Guido, Huober, Jens, Rhiem, Kerstin, Costa, Serban, Altmüller, Janine, Hanusch, Claus, Thiele, Holger, Müller, Volkmar, Nürnberg, Peter, Karn, Thomas, Nekljudova, Valentina, Untch, Michael, von Minckwitz, Gunter, Schmutzler, Rita K.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Medical Association 2017
Konular:
Original Investigation
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5710508/
https://ncbi.nlm.nih.gov/pubmed/28715532
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.1007
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller